Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brontictuzumab
- Development stage
- Phase 1
- Lead developer
- Mereo BioPharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Brontictuzumab is a humanized monoclonal antibody that targets the Notch1 receptor. By binding to Notch1 on the cell surface, it inhibits Notch-mediated signaling, which can suppress tumor cell proliferation and disrupt cancer stem cell pathways. Brontictuzumab was developed for the treatment of various cancers, including adenoid cystic carcinoma and other solid tumors with evidence of Notch pathway activation. The drug was originally developed by OncoMed Pharmaceuticals and later by Mereo BioPharma following acquisition[1][3][5][7].
- Other names
- Anti-Notch 1 monoclonal antibodyAnti-Notch1 monoclonal antibodyAnti-Notch-1 monoclonal antibodyAnti-Notch 1Anti-Notch1Anti-Notch-1OMP-52M51OMP52M51OMP 52M51brontictuzumab
02
Targets
NOTCH (Neurogenic locus notch homolog protein 3)
Beyond the preview
Go deeper on brontictuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brontictuzumab.